Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMPOUND 65 vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD)
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Terminal elimination half-life is 8-12 hours in healthy adults; prolonged to 15-20 hours in hepatic impairment; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Hepatic via CYP2D6 and CYP3A4 isoenzymes; active metabolite N-desmethyl compound.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism with fecal elimination of metabolites accounts for 50-60%; biliary excretion is minimal (<5%).
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
95-98% bound to serum albumin and alpha-1-acid glycoprotein.
>99% bound to albumin; saturable at high concentrations.
0.8-1.2 L/kg, indicating extensive tissue distribution.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Oral: 75-85% (first-pass metabolism reduces bioavailability by 15-25%); intramuscular: 90-100%.
Oral: ~95%; immediate-release formulation.
GFR 30-50 m L/min: 25 mg every 12 hours; GFR <30 m L/min: 25 mg every 24 hours; not recommended in dialysis.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 12.5 mg every 12 hours; Child-Pugh C: not recommended.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Children ≥12 years: 12.5-25 mg orally every 6-8 hours as needed; maximum 75 mg/day. Children <12 years: not established.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Start at 12.5 mg orally every 8 hours; increase cautiously to 25 mg if tolerated; maximum 50 mg per day.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
WARNING: Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Serotonin syndrome,Increased risk of bleeding,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Concomitant use with MAOIs or within 14 days of MAOI therapy,Concomitant use with pimozide,Known hypersensitivity to COMPOUND 65 or any inactive ingredients
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may increase propoxyphene levels by inhibiting CYP3A4, potentially leading to toxicity. High-fat meals may delay absorption but not significantly alter overall exposure. Maintain adequate hydration to prevent constipation.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal complications including withdrawal syndrome and respiratory depression at delivery.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Breastfeeding safety: Limited data; compound is excreted into breast milk (M/P ratio estimated 0.80-1.20 based on molecular properties). Caution advised due to potential for infant sedation and withdrawal. Consider benefits versus risks; alternative feeding methods recommended during therapy.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Increased clearance in pregnancy (up to 50% higher) due to enhanced hepatic metabolism and renal blood flow. Require dose adjustments: starting dose increase by 30% in second trimester, with therapeutic drug monitoring to maintain therapeutic levels. Postpartum return to pre-pregnancy dosing.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
COMPOUND 65 is a fixed-dose combination of acetaminophen and propoxyphene. Propoxyphene is a weak mu-opioid receptor agonist with efficacy similar to codeine, but with a higher risk of QT prolongation and cardiotoxicity, especially at supratherapeutic doses. Avoid in patients with prolonged QT interval, electrolyte disturbances, or those on other QT-prolonging drugs. Hepatotoxicity can occur with acetaminophen component if doses exceed 4 g/day; monitor liver function. Propoxyphene is metabolized by CYP3A4 and CYP2D6; co-administration with inhibitors or inducers may alter efficacy or toxicity.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Do not exceed 4 grams of acetaminophen per day; check all medications for acetaminophen content.,Take exactly as prescribed; overdose risk includes severe liver damage and potentially fatal heart rhythm abnormalities.,Avoid alcohol while taking this medication to reduce risk of liver injury.,Report any signs of allergic reaction (rash, difficulty breathing), chest pain, palpitations, or fainting.,This medication may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how it affects you.,Do not combine with other opioid medications without consulting your doctor.,Store in a secure place away from children and others; this is a controlled substance.,Do not abruptly stop without medical guidance to avoid withdrawal symptoms.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMPOUND 65 vs ALEVE, answered by our medical review team.
COMPOUND 65 is a Analgesic Combination (Opioid + NSAID) that works by COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMPOUND 65 and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMPOUND 65 is: 25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMPOUND 65 and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMPOUND 65 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimest. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.